Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Integrum AB's Days Sales Outstanding for the
three
months ended in Apr. 2026 was 99.2.
Integrum AB's Days Inventory for the
three
months ended in Apr. 2026 was 300.84.
Integrum AB's Days Payable for the
three
months ended in Apr. 2026 was 68.38.
Therefore, Integrum AB's Cash Conversion Cycle (CCC) for the
three
months ended in Apr. 2026 was 331.66.
Integrum AB (OSTO:INTEG B) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Integrum AB Cash Conversion Cycle Related Terms
Integrum AB Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Integrum AB's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:INTEG B vs ABT, SYK, MDT: Cash Conversion Cycle Comparison
For the Medical Devices subindustry, Integrum AB's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integrum AB Cash Conversion Cycle vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Integrum AB's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Integrum AB's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Integrum AB's Cash Conversion Cycle for the fiscal year that ended in Apr. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integrum AB (OSTO:INTEG B) has a Cash Conversion Cycle of 331.66 as of Apr. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Integrum AB and its competitors.
Is Integrum AB's Cash Conversion Cycle too high?
Integrum AB's current Cash Conversion Cycle is 331.66. The Medical Devices & Instruments industry median Cash Conversion Cycle is 157.71. Integrum AB's value of 331.66 is 110.3% above this industry median. Overall, Integrum AB has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Integrum AB's Cash Conversion Cycle compare to ABT and SYK?
Integrum AB's Cash Conversion Cycle of 331.66 can be compared against companies in the Medical Devices & Instruments industry. The industry median Cash Conversion Cycle is 157.71. Integrum AB's value of 331.66 is 110.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Devices & Instruments company?
The median Cash Conversion Cycle among Medical Devices & Instruments companies is 157.71, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Integrum AB's current Cash Conversion Cycle of 331.66 is 110.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Integrum AB and its competitors. For the Medical Devices & Instruments industry, the median Cash Conversion Cycle is 157.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integrum AB's current Cash Conversion Cycle is 331.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integrum AB stock overvalued right now?
Based on GuruFocus' analysis, Integrum AB (OSTO:INTEG B) is currently considered Possible Value Trap. The stock's GF Value™ is kr17.75, compared to a current price of kr7.96 — trading 55.2% below its estimated fair value. The current Cash Conversion Cycle is 331.66 and 110.3% above the Medical Devices & Instruments industry median of 157.71. Integrum AB's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Integrum AB (OSTO:INTEG B), the current Cash Conversion Cycle is 331.66 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integrum AB (OSTO:INTEG B) Overvalued in 2026?
Based on GuruFocus' analysis, Integrum AB stock appears to be undervalued.
The current stock price of kr7.96 is trading 55.2% below its estimated GF Value™ of kr17.75.
GuruFocus considers Integrum AB to be Possible Value Trap.
Key valuation signals for OSTO:INTEG B:
Cash Conversion Cycle: 331.66
GF Value™: kr17.75 vs. price of kr7.96 (55.2% below fair value)
Industry Position: 110.3% above the Medical Devices & Instruments median
No single metric tells the full story. See the OSTO:INTEG B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integrum AB provides the system for bone-anchored prostheses that improves the lives of people with amputations. Its solutions include OPRA implant system, Neural prosthetics, Phantom limb pain treatment, and Prosthetic components. The company is also engaged in developing technology for mind-controlled prostheses and treatment for phantom limb pain.
53GF Score
Get the complete analysis for OSTO:INTEG B
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:INTEG B has been successfully added to your 
